Beyond the case for NBS in South Africa. Chris Vorster 28/05/2016

Similar documents
HA Convention 2016 Master course How to Handle Abnormal Newborn Metabolic Screening Results Causes, Management and Follow up

For Your Baby s Health Department of Health

Overview of Newborn Screening, Potential Uses of Residual Dried Blood Spots, and Protection of Privacy

Newborn Screening: Focus on Treatment

Positive Newborn Screens: What do you do next?

Routine Newborn Screening, Testing the Newborn Inherited Metabolic Disorders Update August 2015

Newborn Screening in Manitoba. Information for Health Care Providers

[R23-13-MET/HRG] STATE OF RHODE ISLAND AND PROVIDENCE PLANTATIONS DEPARTMENT OF HEALTH. February October October 1992 (E) September 1995

NEWBORN SCREENING. in Massachusetts: Answers for You and Your Baby. University of Massachusetts Medical School

Most common is the congenital adrenogenital syndrome (AGS) or congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency.

TIMELINESS OF NEWBORN SCREENING: RECOMMENDATIONS FROM ADVISORY COMMITTEE ON HERITABLE DISORDERS IN NEWBORNS AND CHILDREN

Newborn Screening & Methods for Diagnosing Inborn Errors of Metabolism

A Guide for Prenatal Educators

The Compelling Benefits of Routine 2 nd NBS: A Fifteen-Year Review in Washington State. Saving lives with a simple blood spot

Newborn Screen & Development Facts about the genetic diseases new since March 2006 (Excluding Cystic Fibrosis)

(f) "Birthing center" means any facility that is licensed by the Georgia Department of Community Health as a birthing center;

Title: Assessing Recommendations Related To Timeliness of Newborn Screening

Inborn Errors of Metabolism. Metabolic Pathway. Digestion and Fasting. How is Expanded Newborn Screening Different? MS/MS. The body is a factory.

Newborn Screening: Blood Spot Disorders

Newborn Screening in Washington State Saving lives with a simple blood spot

MISSOURI DEPARTMENT OF HEALTH AND SENIOR SERVICES

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 12/19/17 SECTION: MEDICINE LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:

NEWBORN SCREENING. in Massachusetts: Information for You and Your Baby. University of Massachusetts Medical School

Considerations in Choosing Screening Conditions: One (US) Approach

NEWBORN SCREENING. health.mo.gov/newbornscreening MISSOURI DEPARTMENT OF HEALTH AND SENIOR SERVICES

Newborn Screening: What s New?

NEWBORN METABOLIC SCREEN, MINNESOTA

Further expansion of the neonatal screening panel in the Netherlands

Inborn Errors of Metabolism (IEM)

Metabolic Changes in ASD. Norma J. Arciniegas, MD Simón E. Carlo, MD Instituto Filius

BIOTIN (BIOTINIDASE) DEFICIENCY Marc E. Tischler, PhD; University of Arizona

GUIDE TO NEWBORN SCREENING PROGRAMME

Lynne A. Wolfe, MS, ACNP, PNP, BC Department of Genetics Yale School of Medicine

INBORN ERRORS OF METABOLISM (IEM) IAP UG Teaching slides

Medical Foods for Inborn Errors of Metabolism

Newborn screening for additional metabolic diseases using second-tier strategies Juergen G. Okun, PhD

Newborn Metabolic Screening Programme Annual Report

Methylmalonic aciduria

Newborn bloodspot testing

The spectrum and outcome of the. neonates with inborn errors of. metabolism at a tertiary care hospital

Newborn Metabolic Screening Programme. Annual Report

Newborn Bloodspot Screening Information for parents

Newborn Bloodspot Screening Information for parents

Clinical Management of Organic Acidemias and OAA Natural History Registry. Kim Chapman MD PhD Children s National Rare Disease Institute

Newborn Metabolic Screening Programme

Assessing Mothers Knowledge of the Wisconsin Newborn Screening Program. Sara Wolfgram UW Master of Public Health Symposium August 11, 2006

Guideline for the diagnosis and management of isovaleryl-coa-dehydrogenase deficiency (isovaleric acidemia) - a systematic review -

Inborn Errors of Metabolism Clinical Approach to Diagnosis and Treatment

Attachment 1. Newborn Screening Program Description

Nutritional Management of Inborn Errors of Metabolism. Kay Davis, RD, CSP Esther Berenhaut, RD, CSP, CSR Aug 28, 2017

Diagnose a broad range of metabolic disorders with a single test, Global MAPS

2015 Annual Report for New Mexico s Newborn Screening (NBS) Program

Metabolic Disorders. Chapter Thomson - Wadsworth

Short and Long Term Stability of 3-Hydroxy acylcarnitines Enriched Dried Blood Spots Stored at Various Temperatures and Humidities

Coverage Guidelines: Oral Formula: Rhode Island Products

Pilot Study of Newborn Screening (NBS) for Inborn Errors of Metabolism (IEM) in Collaboration with Department of Health and Hospital Authority

OVERVIEW M ET AB OL IS M OF FR EE FA TT Y AC ID S

Employee Benefits & Executive Compensation ADVISORY

How MS/MS Revolutionized Newborn Screening

Inborn Errors of Metabolism From Neonatal Screening to Metabolic Pathways

PKU gel Unflavored 1 year and older Powder 30x24g packets B4162

Proposal for EXPANDED NEWBORN SCREENING

Newborn Bloodspot Screening (NBS) Training for Health Visitors. December 2017

So Much More Than The PKU Test

Introduction to Organic Acidemias. Hilary Vernon, MD PhD Assistant Professor of Genetic Medicine Johns Hopkins University 7.25.

For the Ongoing Management of Babies under 1 year old.

Screening Newborns for Congenital Disorders

Arizona Newborn Screening Program

What s new in newborn screening?

METABOLISM OF AMINO ACIDS

Suspected Metabolic Disease in the Newborn Period Acute Management "What do I do?" Barbara Marriage, PhD RD Abbott Nutrition

Screening Newborns for Inborn Errors of Metabolism by Tandem Mass Spectrometry

Subject: Enteral Formulas

Atlas of Genetics and Cytogenetics in Oncology and Haematology

Newborn Screening in Japan: Restructuring for the New Era

State of the Art of Rare Disease Activities in EU Member States and Other European Countries. Slovak Republic Report

Tandem Mass Neonatal Screening in Taiwan Report from One Center

Amino Acid Oxidation and the Urea Cycle

Neonatal Screening for Inborn Errors of Metabolism Using Tandem Mass Spectrometry: Experience of the Pilot Study in Andhra Pradesh, India

Joshua Hellmann Foundation Newborn Metabolic Screening Program Clinical Protocol

Secondary Energy Deficiencies in Organic Acidemias. Kimberly A Chapman MD PhD Children s National July 26, 2014

Newborn screening for congenital metabolic diseases Optional out-of-pocket tests Information Sheet

Washington State Newborn Screening

Health Chapter ALABAMA STATE BOARD OF HEALTH ALABAMA DEPARTMENT OF PUBLIC HEALTH BUREAU OF FAMILY HEALTH SERVICES ADMINISTRATIVE CODE

Practitioner s Manual

Assessing the follow-up of BART hemoglobin reported by the Wisconsin Newborn Screening Laboratory

Health and Wellness for all Arizonans. azdhs.gov

Post mortem investigation of Inherited Metabolic Disease - the last opportunity for a diagnosis -

Annual Report Calendar Year 2015

Comprehensive cost-utility analysis of newborn screening strategies Carroll A E, Downs S M

NEONATAL SCREENING FOR INBORN ERRORS OF METABOLISM OUR EXPERIENCE AT CABRI, GULF MEDICAL UNIVERSITY

Original Effective Date: 9/10/09

ICD-10 Physician Education. Medical Genetics

For healthcare professionals Methylmalonic Acidurias

Metabolic Emergencies and the Pediatrician

Information for health professionals

Summary. Syndromic versus Etiologic. Definitions. Why does it matter? ASD=autism

A rough guide to Acylcarnitines

Organic acidaemias (OAs) & Urea cycle disorders (UCDs) PRESENTATION & MANAGEMENT

Sequencing in Newborn Screening Introduction and Background

Transcription:

Beyond the case for NBS in South Africa Chris Vorster 28/05/2016

The case for NBS in SA Economic justification Cost Utility analysis = Cost/QALY GDP/Capita Immediate implementation (WHO) Political justification Genetic and congenital conditions become important once the Infant Mortality Rate < 50/1000 Human rights SA constitution Ch 2 Section 28(c) UN Convention on the Rights of the Child Art 24(1) & 24(2) Laboratory and Clinical capability Medical Aids and Public Health Expected clinical experience

Why beyond the case for NBS in SA 400 Screens per month Reimbursed by Discovery Health LIMS implementation and interfacing Aggressive marketing by Next Biosciences First advisory panel meeting Publication in the SAMJ to follow Personal feedback from paediatricians

Next Biosciences initiative Role of Next in NBS Permission from practising paediatricians Market the service to expecting parents Arrange for collection in collaboration with Ampath Manage all correspondence and recollections Only involve paediatrician when required Initiatives (since mid February) 127 paediatricians 379 Gynaecologists 53 antenatal classes

Primary screening disorders 2016 Rationale What can we screen for? What does the rest of the world screen for? We should modify it over time. Amino Acid Disorders 1 Citrullinemia, Type I 2 Classic Phenylketonuria 3 Homocystinuria 4 Maple Syrup Urine Disease 5 Tyrosinemia, Type I Organic acid disorders 6 3-Hydroxy-3-Methyglutaric Aciduria 7 3-Methylcrotonyl-CoA Carboxylase Deficiency 8 Glutaric Acidemia Type I 9 Holocarboxylase Synthase Deficiency 10 Isovaleric Acidemia 11 Methylmalonic Acidemia (Cobalamin disorders) 12 Methylmalonic Acidemia (methylmalonyl-coa mutase) 13 Propionic Acidemia 14 ß-Ketothiolase Deficiency Disorders of fatty acid oxidation 15 Carnitine Uptake Defect/Carnitine Transport Defect 16 Medium-chain Acyl-CoA Dehydrogenase Deficiency 17 Very Long-chain Acyl-CoA Dehydrogenase Deficiency Disorders of carbohydrate metabolism 18 Classic Galactosemia Endocrine disorders 19 Congenital adrenal hyperplasia 20 Primary Congenital Hypothyroidism 21 Biotinidase Deficiency 22 Cystic Fibrosis Other Disorders

Primary conditions Secondary conditions Primary Amino Acid Disorders screening disorders 2016 Phe Classic phenylketonuria BH4 biosynthesis or regeneration Cit Citrullinemia type I Citrullinemia type II, Argininosuccunic aciduria, Pyrovate carboxylase deficiency Methyladenosyltrasferase deficiency, Glycine N-methyltransferase deficiency, AdoHcy Met Homocystinuria (CBS deficiency) From an analyte perspective Hydrolase deficiency Tyr Tyrosinemia type I Tyrosinemia Type II, Tyrosinemia Type III Xle Maple syrup urine disease Hydroxyproline (Benign hydroxyprolinemia) Organic Acid Disorders C3 Methylmalonic acidemia (mutase deficiency), Methylmalonic acidemia (Cobalamin disorders), Propionic acidemia Succinyl-CoA synthase deficiency, Cblc, CblD, CblF, TC-II deficiency C5 Isovaleric acidemia Short/Branched chain Acyl-CoA dehydrogenase deficiency C5DC Glutaric acidemia type I Holocarboxylase Synthase Deficiency, 3-Methylcrotonyl-CoA Carboxylase Deficiency, 2-Methyl-3-OH-Butyric acidemia C5OH 3-Hydroxy-3-Methyglutaric Aciduria, ß-Ketothiolase Deficiency, Biotinidase Deficiency 3-Methylglutaconic aciduria type 1 Disorder of Fatty Acid Oxidation LCFA C16, C16OH, C14, Very long-chain Acyl-CoA dehydrogenase deficiency, (Trifunctional protein deficiency), Carnitiene:Acylcarnitine translocase deficiency C14:1 (Long chain 3-OH-Acyl-CoA dehydrogenase deficiency) Carnitine palmitoyltransferase I & II deficiency MCFA C10, C10:1, C8, C6 Medium-chain Acyl-CoA dehydrogenase deficiency 2,4-Dienoyl-CoA reductase deficiency Other FA Carnitine uptake disorder Glutaric acidemia Type II, Medium/Short-chain 3-OH-Acyl-CoA dhydrogenase deficiency Medium-chain ketoacyl_coa dehydrogenase deficiency, Short-chain Acyl-CoA dehydrogenase deficiency Disorders of Carbohydrate Metabolism Gal-1-P Classic Galactosemia Endocrine Disorders TSH Congenital Hypothyroidism 17-OH-P Congenital Adrnal Hyperplasia Other Disorders Biotinidase enzyme activity Biotinidase deficiency IRT Cystic Fibrosis Congential heart disease, Hepatic and gastrointestinal disease, Prematurity, Trisomy, CDG disorder, Etc.

Most Common NBS conditions in SA Condition NBS Cases (confirmed) Metabolic lab SA Incidence PKU 1 4.1% 1:100 000 (Black) <1:10 000 (White) Tyrosinemia Type I 0 5.4% Incidence ref Sub-Saharan PKU patients in UK Ann Hum Genet (2008) 72,65-71 Medical Genetics in SA J Med Genet (1990) 27,760-779 Glutaric acidemia Type I 1 3.8% 1:5 000 (Black) GA-I in SA - Mol Gen Metab (2010) 178-182 Isovaleric acidemia 2 4.5% Methylmalonic acidemia 3 5.7% Propionic acidemia 2 6.3% Galactosemia 2 5.5% 1:14 000 (Black) Galactosemia in CT, SA BMC pediatrics (2002),2:7 Congenital Hypothyroidism 4 1:4 000 (White) Medical Genetics in SA J Med Genet (1990) 27,760-779 Cystic Fibrosis NA 1:2 000 (White) 1:12 000 (Mixed) 1:32 000 (black) Biotinidase deficiency 2 1.7% South Arrican Cystic Fibrosis Trust Website (MCAD) 0 1.6%

Presentation and management Condition Discipline Management Treatment Care complexity PKU Neurology Dietician Diet High High Tyrosinemia Type I Gastroenterology Gastroenterology NTBC, Liver transplant Very high High Glutaric acidemia Type I Neurology Dietician, General paediatrician Low lysine diet, Carnitine, Intermittent glucose Low-Medium Isovaleric acidemia Neurology Dietician, General paediatrician Low protein diet, Glycine, Carnitine Low Low Methylmalonic acidemia Neurology Dietician, General paediatrician Low protein diet, Vit B12, Carnitine Low Low Propionic acidemia Neurology Dietician, General paediatrician, Specialist support Care Cost Low Low protein diet, Other Medium Low Galactosemia Gastroenterology Dietician, General paediatrician Avoid galactose Low Low Congenital Hypothyroidism Endocrinology Dietician, General paediatrician Eltroxin Low Low Cystic Fibrosis Pulmonology Paediatric pulmonologist Medium High Biotinidase deficiency Neurology General paediatrician Biotin Low Low (MCAD) Neurology Dietician, General paediatrician Avoid fasting Medium Low High

Presentation and management Condition Discipline Management Treatment Care complexity PKU Neurology Dietician Diet High High Tyrosinemia Type I Gastroenterology Gastroenterology NTBC, Liver transplant Very high High Glutaric acidemia Type I Neurology Dietician, General paediatrician Low lysine diet, Carnitine, Intermittent glucose Low-Medium Isovaleric acidemia Neurology Dietician, General paediatrician Low protein diet, Glycine, Carnitine Low Low Methylmalonic acidemia Neurology Dietician, General paediatrician Low protein diet, Vit B12, Carnitine Low Low Propionic acidemia Neurology Dietician, General paediatrician, Specialist support Care Cost Low Low protein diet, Other Medium Low Galactosemia Gastroenterology Dietician, General paediatrician Avoid galactose Low Low Congenital Hypothyroidism Endocrinology Dietician, General paediatrician Eltroxin Low Low Cystic Fibrosis Pulmonology Paediatric pulmonologist Medium High Biotinidase deficiency Neurology General paediatrician Biotin Low Low (MCAD) Neurology Dietician, General paediatrician Avoid fasting Medium Low High

Phenylalanine Key clinical findings Mental retardation Hypopigmentation Differential diagnosis Classical PKU Very high Phe, Hypertonia BH4 synthesis or regeneration Moderate Phe, Mixed hyper/hypotonia Movement disorders Non-PKU hyperphenylalaninemia Treatment principles Diet Kuvan (PKU responsive & BH4) Neurotransmitter precursors (BH4) Proposed SA Protocol Phe and Phe/Tyr ratio Repeat NBS AA analysis (± OA analysis) Initiate treatment if Phe > 360umol/L DBS biopterin and neopterin?residual hyperphenylalaninemia Blau & Duran 2014

Tyrosine Differential Diagnosis Type I Tyrosinemia Type II & III Tyrosinemia Key clinical findings Type I Liver Failure/Cirrhosis/Carcinoma Renal Tupbulopathy / Failure Type II Mental retardation Corneal erosion & Hyperkeratosis Treatment principles Diet Nitisinone / Liver transplant (Type I) Proposed SA protocol Tyrosine (umol/l) 150 250 Repeat NBS >250 / Repeat >150 Succinylacetone? Tyr > 150, SUAC negative ACMG 2009

Glutarylcarnitine Key clinical findings Macrocephaly & Hypotonia Movement disorder Reversible Irreversible Acute / Insidious Characteristic MRI ± Subdural haemorrhage Low excretors Treatment principles Diet Carnitine & Intermittent glucose Proposed SA protocol C5DC Repeat screen sac uoa (3-OH-Glutaric acid) Metabolic investigation negative White No further action Black A239T mutation Then no further action

Propionylcarnitine (C3) & Isovalerylcarnitine (C5) Key clinical findings Feeding difficulties Encephalopathic crisis AGAP Metabolic acidosis Ammonia & Ketosis Cytopenia Differential diagnosis Isovaleric acidemia (C5) Propionic acidemia (C3) Methylmalonic acidemia (C3) CblA & CblB (C3) Treatment principles Diet Ketone dipstix Carnitine IVA Glycine MMA Hydroxycobalamine responsiveness Proposed SA protocol C5 Repeat screen sac & uoa C3 sac & uoa 3-OH-PA Propionic acidemia Methylmalonic acid See next Methylmalonic acid phomocysteine Test mother for Vit B12 deficiency Methylmalonyl mutase deficiency Cobalamine synthesis (Cbl A & B) Both will have normal homocysteine Cannot distinguish without enzyme analysis, complementation studies and genetics

Galactosemia Clinical overview Jaundice (± E. coli sepsis) Liver failure/cirrhosis Cataracts Treatment principles Avoid lactose/galactose Treat hypergonadotrophic hypogonadism in females!? Breast feeding interruption!? Gal-1-P <0.6 Normal (CDC uses 0.3) 0.6 1.2 > 1.2 Follow-up NBS Breast feeding under clinical monitoring Follow-up NBS GALT enzyme analysis

Biotinidase Clinical overview Seizures, Hypotonia, Movement disorder Skin rash, Alopecia Treatment BIOT 0/- Biotin 5 20mg / day BIOT partial? Biotin 1 5mg / day Biotin (not biocytin) Tablet (not liquid) Biotinidase %activity of normal 0% BIOT 0 <10% BIOT - 10-30% BIOT partial Derived biochemical genotype Follow up sample + Mother & Father & 2 Controls Carrier 50% Partial carrier 75%

Conclusions Seamless NBS service Legal implications of not informing patients about availability Urgent need for advisory board Customized test menu including reflex testing